• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    10/20/23 1:31:02 PM ET
    $ADIL
    $ARAV
    $BCEL
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADIL alert in real time by email

    Gainers

    • Aravive (NASDAQ:ARAV) shares rose 67.5% to $0.24 during Friday's regular session. As of 13:30 EST, this security is trading at a volume of 90.0 million shares, making up 979.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $17.3 million.
    • Lipella Pharmaceuticals (NASDAQ:LIPO) stock moved upwards by 42.27% to $2.29. Lipella Pharmaceuticals's stock is trading at a volume of 39.3 million shares as of 13:30 EST. This is 574673.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $13.2 million.
    • Sagimet Biosciences (NASDAQ:SGMT) shares rose 25.27% to $5.72. As of 13:30 EST, this security is trading at a volume of 70.1K shares, making up 54.7% of its average full-day volume over the last 100 days. The company's market cap stands at $130.9 million.
    • Catalyst Biosciences (NASDAQ:CBIO) shares increased by 23.16% to $0.49. Catalyst Biosciences's stock is trading at a volume of 2.6 million shares as of 13:30 EST. This is 717.8% of its average full-day volume over the last 100 days. The company's market cap stands at $18.7 million.
    • Redhill Biopharma (NASDAQ:RDHL) shares rose 20.78% to $0.53. Trading volume for Redhill Biopharma's stock is 1.3 million as of 13:30 EST. This is 89.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.1 million.
    • Eiger BioPharmaceuticals (NASDAQ:EIGR) stock rose 17.38% to $0.32. The current volume of 117.0K shares is 39.3% of Eiger BioPharmaceuticals's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $14.1 million.

    Losers

    • Processa Pharma (NASDAQ:PCSA) stock fell 32.4% to $0.36 during Friday's regular session. As of 13:30 EST, this security is trading at a volume of 2.8 million shares, making up 157.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $8.9 million.
    • Atreca (NASDAQ:BCEL) stock declined by 25.7% to $0.27. Atreca's stock is trading at a volume of 2.3 million shares as of 13:30 EST. This is 140.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $10.7 million.
    • RVL Pharmaceuticals (NASDAQ:RVLP) shares declined by 25.55% to $0.03. Trading volume for RVL Pharmaceuticals's stock is 38.3 million as of 13:30 EST. This is 180.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.4 million.
    • Adial Pharmaceuticals (NASDAQ:ADIL) stock declined by 22.35% to $2.19. The market value of their outstanding shares is at $2.6 million.
    • Renovaro Biosciences (NASDAQ:RENB) stock decreased by 20.87% to $2.73. Renovaro Biosciences's stock is trading at a volume of 397.0K shares as of 13:30 EST. This is 38.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $179.3 million.
    • Outlook Therapeutics (NASDAQ:OTLK) shares decreased by 20.0% to $0.53. As of 13:30 EST, Outlook Therapeutics's stock is trading at a volume of 18.1 million, which is 213.9% of its average full-day volume over the last 100 days. The company's market cap stands at $137.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADIL
    $ARAV
    $BCEL
    $CBIO

    CompanyDatePrice TargetRatingAnalyst
    Sagimet Biosciences Inc.
    $SGMT
    2/3/2026$27.00Buy
    Guggenheim
    Sagimet Biosciences Inc.
    $SGMT
    1/28/2026$8.00Equal Weight
    Barclays
    Crescent Biopharma Inc.
    $CBIO
    1/28/2026$35.00Overweight
    Piper Sandler
    Crescent Biopharma Inc.
    $CBIO
    1/21/2026$35.00Buy
    Guggenheim
    Outlook Therapeutics Inc.
    $OTLK
    8/29/2025Buy → Neutral
    H.C. Wainwright
    Outlook Therapeutics Inc.
    $OTLK
    8/28/2025Buy → Neutral
    Guggenheim
    Crescent Biopharma Inc.
    $CBIO
    8/25/2025$26.00Buy
    Jefferies
    Sagimet Biosciences Inc.
    $SGMT
    8/11/2025$28.00Outperform
    Wedbush
    More analyst ratings

    $ADIL
    $ARAV
    $BCEL
    $CBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Crescent Biopharma Announces Grants of Inducement Awards

    WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 45,675 shares of the Company's ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the "Inducement Plan"). The options were approved on March 5, 2026 and were material to each employee's acceptanc

    3/6/26 4:15:00 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

    GLEN ALLEN, Va., March 06, 2026 (GLOBE NEWSWIRE) --  Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2025 fiscal year ended December 31, 2025. Key Highlights: Regulatory Progress: Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04's pharmacologic profile and regulatory strategy.Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company's proposed in vitro bri

    3/6/26 8:00:00 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)

    ISELIN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today provided an update following its recent Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the December 30, 2025 Complete Response Letter (CRL) for the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg). The Type A meeting was conducted to clarify the outstanding issue identified in the CRL regarding substantial evidence of effectiveness and to discuss potential paths forward for regulatory approval. "We appreciate the F

    3/5/26 4:15:00 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADIL
    $ARAV
    $BCEL
    $CBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal & Admin. Officer Rozek Elizabeth was granted 44,000 units of Series A Common Stock, increasing direct ownership by 23% to 234,959 units (SEC Form 4)

    4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

    2/20/26 4:43:57 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Martins Eduardo Bruno was granted 44,000 units of Series A Common Stock, increasing direct ownership by 43% to 147,296 units (SEC Form 4)

    4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

    2/20/26 4:42:48 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Happel David was granted 128,000 units of Series A Common Stock, increasing direct ownership by 19% to 805,621 units (SEC Form 4)

    4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

    2/20/26 4:41:03 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ARAV
    $BCEL
    $CBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairmount Funds Management Llc bought $18,237,600 worth of Ordinary Shares (1,360,000 units at $13.41) (SEC Form 4)

    4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)

    12/8/25 4:30:15 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Yorke Justin W bought $9,889 worth of shares (12,400 units at $0.80) (SEC Form 4)

    4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

    1/31/25 5:06:27 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Ng George K bought $69,542 worth of shares (87,200 units at $0.80) (SEC Form 4)

    4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

    1/29/25 5:05:00 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ARAV
    $BCEL
    $CBIO
    SEC Filings

    View All

    Adial Pharmaceuticals Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)

    3/6/26 8:15:35 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Adial Pharmaceuticals Inc

    10-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)

    3/5/26 5:03:27 PM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Outlook Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)

    3/5/26 5:01:18 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADIL
    $ARAV
    $BCEL
    $CBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Sagimet Biosciences with a new price target

    Guggenheim initiated coverage of Sagimet Biosciences with a rating of Buy and set a new price target of $27.00

    2/3/26 7:59:13 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Sagimet Biosciences with a new price target

    Barclays initiated coverage of Sagimet Biosciences with a rating of Equal Weight and set a new price target of $8.00

    1/28/26 7:18:50 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Crescent Biopharma with a new price target

    Piper Sandler initiated coverage of Crescent Biopharma with a rating of Overweight and set a new price target of $35.00

    1/28/26 7:10:21 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ARAV
    $BCEL
    $CBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

    ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development. "We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution," said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. "Laura's two decades of global biotechnology experience spanning corporate strategy, business development and portfolio leadership, and her proven ability to identify, evaluate and execute high-value

    1/6/26 8:35:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer

    Seasoned Leader Brings Deep Experience in Oncology Drug Development as Company Advances Portfolio of Next Generation Therapeutics for Solid Tumors WALTHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced the appointment of Jan Pinkas, Ph.D., as chief scientific officer. Dr. Pinkas brings more than two decades of experience in oncology drug development, leading preclinical and translational research with expertise in multiple modalities, including antibody-drug conjugates (ADCs). "We are thrilled to welcome Ja

    7/8/25 7:30:00 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

    Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographies Career focused on driving business growth and developing an integrated commercial strategy to deliver results ISELIN, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the appointment of Bob Jahr as Chief Executive Officer (CEO). Mr. Jahr has also been appointed to the Outlook Therapeutics Board of Directors. Lawrence A. Kenyon, who has served as Outlook Therapeutics' Chie

    7/1/25 8:05:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADIL
    $ARAV
    $BCEL
    $CBIO
    Financials

    Live finance-specific insights

    View All

    Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

    ISELIN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced financial results for fiscal year 2025. Financial Highlights for the Fiscal Year Ended September 30, 2025 For the fiscal year ended September 30, 2025, Outlook Therapeutics reported net loss attributable to common stockholders of $62.4 million, or $1.79 per basic and diluted share, and $1.4 million of revenue. This compares with net loss attributable to common stockholders of $75.4 million, or $4.06 per basic and diluted share, and no revenue for the prior year.

    12/19/25 8:05:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

     Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy NASHVILLE, Tenn., Oct. 20, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced strategic arrangements with RedHill Biopharma Ltd. (NASDAQ:RDHL), a specialty biopharmaceutical company, to jointly commercialize Talicia®. The FDA-approved oral capsule is indicated for the treatment of Helicobacter pylori infection in adults, a bacterial infection and leading risk factor for gastric cancer.

    10/20/25 9:05:00 AM ET
    $CPIX
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

    Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) invests $4 million in exchange for a 30% ownership stake and joint control in RedHill's Talicia business U.S. co-commercialization partnership designed to accelerate Talicia sales growth, leveraging Cumberland's expanded national sales promotion and marketing support, and deliver significant efficiencies through shared operational responsibility Transaction reinforces RedHill's financial position to advance its broader strategic objectives Patent protected through 2042 and with eight years QIDP market exclusivity, Talicia is:The #1 branded U.S. gastroenterologist-prescribed H. pylori therapy1 Listed first-line H. pylori therapy in American Colle

    10/20/25 9:00:00 AM ET
    $CPIX
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ARAV
    $BCEL
    $CBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sagimet Biosciences Inc.

    SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)

    11/14/24 7:55:59 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

    SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

    11/14/24 5:09:22 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Sagimet Biosciences Inc.

    SC 13G - Sagimet Biosciences Inc. (0001400118) (Subject)

    11/14/24 5:05:18 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care